{
    "1665967817244438528": {
        "author_id": "5383942",
        "created_at": "2023-06-06T06:24:14.000Z",
        "edit_history_tweet_ids": [
            "1665967817244438528"
        ],
        "entities": {
            "hashtags": [
                {
                    "end": 5,
                    "start": 0,
                    "tag": "News"
                },
                {
                    "end": 20,
                    "start": 10,
                    "tag": "Investors"
                },
                {
                    "end": 31,
                    "start": 25,
                    "tag": "Media"
                },
                {
                    "end": 209,
                    "start": 202,
                    "tag": "cancer"
                }
            ],
            "mentions": [
                {
                    "end": 44,
                    "id": "208120290",
                    "start": 37,
                    "username": "US_FDA"
                }
            ]
        },
        "id": "1665967817244438528",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 0,
            "impression_count": 3253,
            "like_count": 9,
            "quote_count": 0,
            "reply_count": 1,
            "retweet_count": 2
        },
        "text": "#News for #Investors and #Media: The @US_FDA has accepted the supplemental Biologics License Application and granted Priority Review for a potential new indication for our immuno-oncology treatment for #cancer patients.  \n\nLearn more:"
    }
}